Remove Communication Remove Documentation Remove Vaccines
article thumbnail

As the Prospect of a Vaccine Approaches, Business and Communications Challenges Are Just Around the Corner

Eye on FDA

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

article thumbnail

High levels of exposure to COVID virus may reduce protection from vaccination, prior infection: Study

Express Pharma

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

Advancing research on human immune systems in India to develop better vaccines

Express Pharma

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Institutional support, such as expert consultants, essential document templates, and protocols for regulatory submissions, is also vital. However, the spotlight has shifted to unravelling the complexities of the human immune system.

Immunity 105
article thumbnail

Healthier Together and philanthropic ventures in tropical disease

European Pharmaceutical Review

A guidance document has been released to support these activities. GSK now has more than 30 potential new vaccines and medicines in 13 high-burden infectious diseases to accelerate, and we must work collectively with urgency to bring these potentially life-saving innovations to people that need them.”.

Vaccines 110
article thumbnail

Building an integrated vector supply to support autologous cell therapy for solid tumours

European Pharmaceutical Review

Within recent years this situation has been further exacerbated by the COVID-19 pandemic: both directly, through viral vaccine manufacture; and indirectly, through instability in global supply chains. Those available commercially include adenoviral-based vaccines by AstraZeneca and Johnson & Johnson.

Vaccines 115
article thumbnail

Dassault Systèmes introduces ‘Emma Twin’ Avatar

Express Pharma

Our virtual twins have been used to swiftly develop COVID-19 vaccines, optimise surgical procedures, and provide patients with a greater understanding of treatment options.